Table 2.
Adults 15–59, 1999–2009, entire population | |||
---|---|---|---|
Deaths/pyrs (rate/1000 pyr) | Unadjusted RR (95% CI) | Adjusted RR† (95% CI) | |
All individuals | P < 0.001 | P < 0.001 | |
0–5 years pre ART | 390/35 626 (10.9) | 1 | 1 |
ART period 1‡ | 71/7713 (9.2) | 0.84 (0.65–1.08) | 0.82 (0.64–1.06) |
ART period 2‡ | 225/33 650 (6.7) | 0.61 (0.52–0.72) | 0.58 (0.50–0.68) |
Stratified by sex | |||
Male | P < 0.001 | P < 0.001 | |
0–5 years pre ART | 185/17 145 (10.8) | 1 | 1 |
ART period 1‡ | 34/3671 (9.3) | 0.86 (0.60–1.24) | 0.84 (0.58–1.20) |
ART period 2‡ | 109/15 907 (6.9) | 0.64 (0.50–0.80) | 0.60 (0.47–0.76) |
Female | P < 0.001 | P < 0.001 | |
0–5 years pre ART | 205/18 481 (11.1) | 1 | 1 |
ART period 1‡ | 37/4042 (9.2) | 0.83 (0.58–1.17) | 0.81 (0.57–1.15) |
ART period 2‡ | 116/17 743 (6.5) | 0.59 (0.47–0.74) | 0.57 (0.45–0.71) |
Stratified by age | |||
15–29 years | P = 0.06 | P = 0.06 | |
0–5 years pre ART | 109/20 447 (5.3) | 1 | 1 |
ART period 1‡ | 21/4259 (4.9) | 0.92 (0.58–1.48) | 0.92 (0.58–1.47) |
ART period 2‡ | 67/17 980 (3.7) | 0.70 (0.52–0.95) | 0.70 (0.51–0.94) |
30–44 years | P < 0.001 | P < 0.001 | |
0–5 years pre ART | 192/9853 (19.5) | 1 | 1 |
ART period 1‡ | 34/2268 (15.0) | 0.77 (0.53–1.11) | 0.77 (0.53–1.11) |
ART period 2‡ | 84/10 046 (8.4) | 0.43 (0.33–0.55) | 0.43 (0.33–0.55) |
45–59 years | P = 0.29 | P = 0.29 | |
0–5 years pre ART | 89/5327 (16.7) | 1 | 1 |
ART period 1‡ | 16/1185 (13.5) | 0.81 (0.47–1.38) | 0.81 (0.47–1.38) |
ART period 2‡ | 74/5624 (13.2) | 0.79 (0.58–1.07) | 0.79 (0.58–1.07) |
ART, antiretroviral therapy; RRs, rate ratios.
ART roll-out defined as 1 January 2004.
Adjusted for sex and age (RRs for all individuals), age (RRs stratified by sex), or sex (RRs stratified by age).
ART period 1 defined as the first year after ART roll-out (1 January 2004 to 1 January 2005). ART period 2 defined as the 4-year period from 1 January 2004 to 31 December 2009).
All estimates include participants whose HIV status was unknown (never tested).